Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of antibiotic treatment on the normal flora and the presence of resistance genes in known carriers of ESBL and VRE
2024-517434-17-01Phase 4Authorised
- Sponsor
- Region Uppsala
- Start
- Oct 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ciprofloxacin and vancomycin in carbapenem-resistant Enterobacterales infection and vancomycin-resistant Enterococcus colonization (VRE) (2 arms), sponsored by Region Uppsala. Planned start Oct 2024; status: authorised.
02
Drugs
ciprofloxacinvancomycin
03
Conditions
carbapenem-resistant Enterobacterales infectionvancomycin-resistant Enterococcus colonization (VRE)
Beyond the preview
Go deeper on 2024-517434-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517434-17-01.